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Plasmid-Mediated Colistin-
Resistant Escherichia coli in
Bacteremia in Switzerland
TO THE EDITOR—Very recently the ﬁrst
plasmid-mediated colistin resistance
(MCR) mechanism Enterobacteriaceae
was reported from animals, food, and pa-
tients [1–4]. Then a series of short stud-
ies, based mainly on retrospective data
and established enterobacterial strain col-
lections, reported further identiﬁcations
of this transmissible colistin-resistant de-
terminant, namely the MCR-1 enzyme,
from worldwide. We coauthored reports
of a urinary tract infection due to an
Escherichia coli strain coexpressing plas-
mid-mediated carbapenemase and colis-
tin resistance genes [5] and a series of
MCR-1–positive isolates among a retro-
spective collection (2004–2005) of E. coli
isolates from diarrheic veal calves in
France [6].
Here, we report 2 cases of bacteremia
associated with E. coli isolates produc-
ing MCR-1 from patients hospitalized
at the regional hospital in Neuchatel,
Switzerland. A 59-year-old man was treat-
ed for acute myeloid leukemia that did not
respond to palliative anticancer treatment.
He was hospitalized in December 2015 for
neutropenic fever of unknown origin. An
E. coli isolate (strain N-A) susceptible to
broad-spectrum cephalosporins grew in
blood cultures. The patient was rapidly
discharged with a ceftriaxone-containing
ambulatory treatment. Two weeks later,
bacteremia developed again with the
same bacterial isolate, which had also ac-
quired an extended-spectrum ß-lactamase
(ESBL) gene.
In December 2015, bacteremia with an
E. coli isolate (strain N-B) developed in
an 88-year-old man. The patient had a his-
tory of multiple urinary tract infections
with a recent 3-week-long treatment with
ciproﬂoxacin for suspected Enterobacter
cloacae prostatitis. He was empirically
treated with ceftriaxone, later relayed with
ertapenem after identiﬁcation of ESBL
production. Neither of those 2 patients
had received previous treatment with poly-
myxins, and neither had traveled abroad in
the past few years or had exposure to farm
animals.
Minimal inhibitory concentrations of
colistin were determined and interpreted
by mean of broth microdilution accord-
ing to the Clinical and Laboratory Stan-
dards Institute guidelines [7], showing
that E. coli isolates N-A and N-B were
resistant with minimal inhibitory con-
centrations of 4 and 16 mg/L, respective-
ly. In addition, E. coli isolate N-A was
resistant to aminopenicillins and ureido-
penicillins, whereas E. coli strain N-B was
resistant to all ß-lactams except cepha-
mycins and carbapenems and to nalidixic
acid, gentamicin, and trimethoprim-
sulfamethoxazole.
Polymerase chain reaction ampliﬁca-
tion was performed with whole-cell DNA
of both strains using primers speciﬁc for
the mcr-1 gene, and results were positive.
Sequencing of the polymerase chain reac-
tion products identiﬁed themcr-1 gene in
both isolates. Plasmid analysis identiﬁed
mcr-1–bearing plasmids of about 30 and
80 kb for E. coli isolates N-A and N-B, re-
spectively, both belonging to the IncFIB
incompatibility group [8]. Those plas-
mids signiﬁcantly differed from the mcr-
1–positive plasmid reported from the
pioneer Chinese study [1]. In addition,
E. coli isolate N-A possessed the narrow-
spectrum ß-lactamase gene blaTEM-1
whereas E. coli isolate N-B possessed the
ESBL gene blaTEM-52.
This report further highlights the silent
spread of the plasmid-mediated mcr-1
gene in community-acquired E. coli. The
extent to which the mcr-1 gene has dis-
seminated among Enterobacteriaceae
remains to be determined; it will be com-
plicated given that MCR-1 confers a low
level of resistance to polymyxins in E. coli
and the common techniques for deter-
mining polymyxin susceptibility in rou-
tine laboratories are not reliable. Such
difﬁculty in detection may explain why
plasmid-MCR has remained silent until
recently, although we now know it has
been circulating for at least for 10 years
[6]. Finally, the rapidity and ease with
which we identiﬁed those 2 additional
cases of MCR-1–producing E. coli strains
in Switzerland is actually very alarming,
given the global implications.
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